Drug intelligence / Profile preview

fuzuloparib + capecitabine + camrelizumab

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of fuzuloparib (a PARP inhibitor), capecitabine (a chemotherapeutic agent), and camrelizumab (a PD-1 inhibitor). This triple combination leverages multiple mechanisms to target cancer cells through DNA damage repair inhibition, cytotoxic effects (via capecitabine's metabolism to 5-fluorouracil), and immune checkpoint inhibition.

Brand names: AiRuiYiAiRuiKaXeloda
Other names: fluzoparibumcamrelizumabumcapecitabinum

Targets

PDCD1 (Programmed cell death protein 1 receptor)PARP2 (Poly (adp-ribose) polymerase 2)TS (Thymidylate synthase)

Beyond the preview

Go deeper on fuzuloparib + capecitabine + camrelizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fuzuloparib + capecitabine + camrelizumab.

Explore the full profile